Literature DB >> 26246357

Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients.

A Calcagno1, C Atzori2, A Romito3, D Vai2, S Audagnotto4, M L Stella4, C Montrucchio4, D Imperiale2, G Di Perri4, S Bonora4.   

Abstract

Blood brain barrier impairment occurs early in the course of infection by HIV and it may persist in a subset of patients despite effective antiretroviral treatment. We tested the hypothesis that HIV-positive patients with dysfunctional blood brain barrier may have altered biomarkers of neuronal damage. In adult HIV-positive highly active antiretroviral treatment (HAART)-treated patients (without central nervous system infections and undergoing lumbar punctures for clinical reasons) cerebrospinal fluid albumin to serum ratios (CSAR), total tau, phosphorylated tau, 1-42 beta amyloid, and neopterin were measured. In 101 adult patients, cerebrospinal fluid-to-serum albumin ratios were 4.8 (3.7-6.1) with 12 patients (11.9%) presenting age-defined impaired blood brain barrier. A significant correlation was observed between CSAR and total tau (p = 0.005), phosphorylated tau (p = 0.008), and 1-42 beta amyloid (p = 0.040). Patients with impaired blood brain barrier showed significantly higher total tau (201.6 vs. 87.3 pg/mL, p = 0.010), phosphorylated tau (35.3 vs. 32.1 ng/mL, p = 0.035), and 1-42 beta amyloid (1134 vs. 830 pg/mL, p = 0.045). Despite effective antiretroviral treatment, blood brain barrier impairment persists in some HIV-positive patients: it is associated with markers of neuronal damage and it was not associated with CSF neopterin concentrations.

Entities:  

Keywords:  Albumin ratio; Blood brain barrier; Neopterin; Phosphorylated tau; Tau

Mesh:

Substances:

Year:  2015        PMID: 26246357     DOI: 10.1007/s13365-015-0371-x

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  24 in total

1.  Amyloid beta-42 (Aβ-42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments.

Authors:  K M Mothapo; F Stelma; M Janssen; R Kessels; S Miners; M M Verbeek; P Koopmans; A van der Ven
Journal:  J Neuroimmunol       Date:  2015-03-21       Impact factor: 3.478

2.  Cortical sources of resting-state EEG rhythms in "experienced" HIV subjects under antiretroviral therapy.

Authors:  Claudio Babiloni; Paola Buffo; Fabrizio Vecchio; Paolo Onorati; Chiara Muratori; Stefano Ferracuti; Paolo Roma; Michele Battuello; Nicole Donato; Giuseppe Noce; Francesco Di Campli; Laura Gianserra; Elisabetta Teti; Antonio Aceti; Andrea Soricelli; Magdalena Viscione; Massimo Andreoni; Paolo M Rossini; Alfredo Pennica
Journal:  Clin Neurophysiol       Date:  2014-02-12       Impact factor: 3.708

3.  Prevalence and predictors of blood-brain barrier damage in the HAART era.

Authors:  A Calcagno; M C Alberione; A Romito; D Imperiale; V Ghisetti; S Audagnotto; F Lipani; S Raviolo; G Di Perri; S Bonora
Journal:  J Neurovirol       Date:  2014-06-28       Impact factor: 2.643

Review 4.  Neuroimaging of HIV-associated neurocognitive disorders (HAND).

Authors:  Beau M Ances; Dima A Hammoud
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

5.  External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients.

Authors:  H Reiber
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

6.  Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism.

Authors:  Eliseo A Eugenin; Janice E Clements; M Christine Zink; Joan W Berman
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

7.  Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

Authors:  S Abdulle; L Hagberg; M Gisslén
Journal:  HIV Med       Date:  2005-05       Impact factor: 3.180

8.  The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Authors:  Edward R Hammond; Rosa M Crum; Glenn J Treisman; Shruti H Mehta; Christina M Marra; David B Clifford; Susan Morgello; David M Simpson; Benjamin B Gelman; Ronald J Ellis; Igor Grant; Scott L Letendre; Justin C McArthur
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

9.  APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.

Authors:  Lucette A Cysique; Timothy Hewitt; Juliana Croitoru-Lamoury; Kevin Taddei; Ralph N Martins; Constance S N Chew; Nicholas N W S Davies; Patricia Price; Bruce J Brew
Journal:  BMC Neurol       Date:  2015-04-01       Impact factor: 2.474

Review 10.  The role of tau protein in HIV-associated neurocognitive disorders.

Authors:  Lecia A M Brown; James Scarola; Adam J Smith; Paul R Sanberg; Jun Tan; Brian Giunta
Journal:  Mol Neurodegener       Date:  2014-10-10       Impact factor: 14.195

View more
  19 in total

1.  Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?

Authors:  S Mornese Pinna; E Scarvaglieri; M G Milia; D Imperiale; V Ghisetti; S Audagnotto; A Prochet; F Lipani; S Bonora; G Di Perri; A Calcagno
Journal:  J Neurovirol       Date:  2017-07-05       Impact factor: 2.643

Review 2.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

Review 3.  Neurological Complications of HIV Infection.

Authors:  Shelli Farhadian; Payal Patel; Serena Spudich
Journal:  Curr Infect Dis Rep       Date:  2017-11-21       Impact factor: 3.725

4.  Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV.

Authors:  Bing Sun; Pranjali Dalvi; Linda Abadjian; Norina Tang; Lynn Pulliam
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

5.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

6.  Alzheimer Dementia in People Living With HIV.

Authors:  Andrea Calcagno; Luigi Celani; Mattia Trunfio; Giancarlo Orofino; Daniele Imperiale; Cristiana Atzori; Vincenzo Arena; Gabriella d'Ettorre; Giovanni Guaraldi; Magnus Gisslen; Giovanni Di Perri
Journal:  Neurol Clin Pract       Date:  2021-10

7.  Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.

Authors:  A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-08       Impact factor: 4.147

Review 8.  Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior.

Authors:  Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-15       Impact factor: 4.147

9.  Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation.

Authors:  Tommaso Lupia; Maria Grazia Milia; Cristiana Atzori; Sara Gianella; Sabrina Audagnotto; Daniele Imperiale; Lorenzo Mighetto; Veronica Pirriatore; Gabriella Gregori; Filippo Lipani; Valeria Ghisetti; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  AIDS       Date:  2020-03-01       Impact factor: 4.632

10.  Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers.

Authors:  Giulia Caligaris; Mattia Trunfio; Valeria Ghisetti; Jessica Cusato; Marco Nigra; Cristiana Atzori; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Diagnostics (Basel)       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.